Overview
Fetal hypertrophic cardiomyopathy (HCM) is a condition characterized by thickening of the fetal heart muscle. It can lead to significant cardiac dysfunction and is associated with various genetic and non-genetic causes.Diagnosis
Diagnosis is typically made via prenatal ultrasound, which may reveal increased myocardial wall thickness 1.
Further evaluation may include fetal echocardiography for detailed assessment of cardiac structure and function 1.Management
Management strategies are primarily supportive and depend on the severity of cardiac compromise and the underlying etiology.
In cases of hydrops fetalis or significant cardiac dysfunction, maternal treatment with medications such as betamethasone or diuretics may be considered 1.Special Populations
Pregnancy: Fetal HCM is a complication that can occur during pregnancy, requiring specialized monitoring and management 1. Monochorionic twin pregnancies have specific management guidelines that include increased ultrasound monitoring 1.Key Recommendations
Monochorionic twin pregnancies require more frequent ultrasound monitoring compared to dichorionic twins 1. (Evidence: Expert opinion)
Prenatal diagnosis of fetal cardiac anomalies, including hypertrophic cardiomyopathy, should prompt detailed fetal echocardiography 1. (Evidence: Expert opinion)
Consider maternal treatment with betamethasone or diuretics for fetal hydrops or significant cardiac dysfunction in the setting of fetal hypertrophic cardiomyopathy 1. (Evidence: Expert opinion)References
1 Lee HS, Abbasi N, Van Mieghem T, Mei-Dan E, Audibert F, Brown R et al.. Guideline No. 440: Management of Monochorionic Twin Pregnancies. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2023. link
2 . Multifetal Gestations: Twin, Triplet, and Higher-Order Multifetal Pregnancies: ACOG Practice Bulletin, Number 231. Obstetrics and gynecology 2021. link